Ilya Pharma was granted € 3M from the SME Instrument, HORIZON 2020, phase 2.
Ilya Pharma, an innovative Swedish pharmaceutical company, develops drug candidates for Proof of Concept in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins.
Ilya Pharma has developed its own proprietary technology platform based on the use of living lactic acid bacteria. Wound healing in skin and mucosa are accelerated as human healing proteins are injected directly into the wounds. The funds from the EU will facilitate continued growth and take the company through the first clinical study and planning of the upcoming Phase II study of its most promising drug candidate, ILP-100, for faster wound healing.
GAEU helped structuring the project and highlight the parts essential in order for the commission to see the potential of the project, even though it was at a very early stage in its development, and very venturous.
"The cooperation with GAEU has been very successful with Ilya Pharma. GAEU's consultants handled the process excellently. They possess eminent knowledge on how to break down a very complex project into smaller, logical activities, and on how the different parts are connected. It feels very good to have GAEU standing beside us in the process when we are to deliver this 18 months project"
Evenlina Vågesjö, CEO, Ilya Pharma